WARN : Please note that some of the values may not be in base currency

Fundamental Analysis of Merrimack Pharmaceuticals Inc - Growth / Value Index


MACK - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Very Poor Score of 12.50
   Price to Book Ratio of 11.39 suggesting that it is very expensive
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning 1.08 -150.97 -13.92 %
Price to Book 3.65 11.54 8.55 % 0.987
Price to Sales 0 0 0 %
Enterprise Value to EBITDA Multiple -102.78 -146.79 -22.16 %


MACK - Profitability Highlights

Profitability Analysis

   Gives Dividend Yield of 57.71 %
   Annual Net Profit in last 3 years is trending up
   Company's Net Profit is increasing for last 5 Quarters
   Company's Profit Before Tax is increasing for last 5 Quarters
   EBITDA is continuously increasing for last 3 Years
   Steady Growth in EPS for last four quarters
   Tsr Profitability Index - Very Poor Score of 7.29
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 337.01 -7.64 4.71 % 90.85
Return On Asset 311.38 -7.47 4.05 % 82.42
Net Profit Margin 0 0 0 % 0
Operating Profit Margin 0 0 0 % 0
EBITDA Margin 0 0 0 % 0


Highlights
Market Cap219866 K
Enterprise Value213877 K
Price/Book TTM3.65
Outstanding Share14531.80 K
Float/ Outstanding Share0.065%
Dividend Yield57.71 %
Share Holding
Guru Numbers
Price/Graham No0.746
Peter Lynch Ratio0
Piotroski F Score3.00
Altman Z Score260.02
Sloan Ratio-0.0011
Peter Lynch Fair Value349.04


MACK - Growth Highlights

Growth Analysis

   Annual sales of the company is increased for three years in a row
   Quarterly sales in last 5 years is trending up
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue NA 100.00 % %
Gross Profit NA 100.00 % %
EBITDA -2081.00 K 7.01 % 36.53 %
Net Profit 200460 K 7.19 % 84004.17 %
EPS 13.96 12.22 % NA


MACK - Stability Highlights

Stability Analysis

   Tsr Stability Index - Excellent Score of 95.00
   Altman Z Score of 259.82 suggests good Stability
   Company is Debt Free
   Net Debt zero balance-sheet with high liquidity
   Cash ratio of 42.80
   Company financial liquidity has improved
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of 0
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0 0 % 0
Cash Ratio 42.80 29.68 %
Quick Ratio 0 0 % 10.78
Shareholders Equity 97.70 0.692 %
Debt to EBITDA 0 0 %


Historical Valuation Ratios of Merrimack Pharmaceuticals Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Merrimack Pharmaceuticals Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Merrimack Pharmaceuticals Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Merrimack Pharmaceuticals Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)